Possible induction of cholinesterase in epileptic patients treated with anticonvulsant drugs: Relationship with lipoprotein levels

Journal of Clinical Pharmacology

Volumn 44, Issue 9, 2004, Pages 974-980

  Tutor Crespo, María J ^a   Hermida, Jesús ^a   Tutor, J Carlos ^a  

^a Instituto de Salud Carlos III   (Spain)

Author keywords

Anticonvulsant drugs; Cholinesterase; Enzyme induction; Lipoproteins

Indexed keywords

ANTICONVULSIVE AGENT; APOLIPOPROTEIN B; CARBAMAZEPINE; CHOLESTEROL; CHOLINESTERASE; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHENOBARBITAL; PHENYTOIN; PHOSPHOLIPID; SACCHARIC ACID; TRIACYLGLYCEROL; VALPROIC ACID; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANTICONVULSANT THERAPY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME INDUCTION; EPILEPSY; FEMALE; HUMAN; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; BODY WEIGHT; CHOLINESTERASES; ENZYME INDUCTION; EPILEPSY; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GLUCARIC ACID; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED;

EID: 4143064650     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004266486     Document Type: Article

References (50)

1. Sawhney AK, Lott JA: Acetylcholinesterase and cholinesterase, in: Lott JA, Wolf PL (eds.), Clinical Enzymology. New York: Field, Rich and Associates, 1986;1-26.
2. McQueen JM: Clinical and analytical considerations in the utilization of cholinesterase measurements. Clin Chim Acta 1995;237:91-105.
3. Henderson AR, Moss DW: Enzymes, in: Burtis CA, Ashwood ER (eds.), Tietz Fundamentals of Clinical Chemistry. 5th ed. Philadelphia: W. B. Saunders, 2001;352-389.
4. Kutty KM, Redheendran R, Murphy D: Serum cholinesterase: function in lipoprotein metabolism. Experientia 1977;33:420-422.
5. Kutty KM: Biological function of cholinesterase. Clin Biochem 1980;13:239-243.
6. Rustemeijer C, Schouten JA, Voerman HJ, Beynen AC, Donker AJM, Heines RJ: Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in type II diabetes mellitus? Clin Sci 2001; 101:29-35.
7. Cucuianu M: Serum γ-glutamyltransferase and/or serum cholinesterase as markers of the metabolic syndrome. Diabetes Care 1999;22:1381-1382.
8. Kutty KM, Payne RH: Serum pseudocholinesterase and very-low-density lipoprotein metabolism. J Clin Lab Anal 1994;8:247-250.
9. Bedeleanu D, Trif I, Lötsch JC, Cucuianu MP: Increased values of antipyrine clearance in type IV hyperlipoproteinemia. Méd Interne 1986;24:183-190.
10. Puche E, García M, García H, Mota C: Probable pseudocholinesterase induction by valproic acid, carbamazepine and phenytoin leading to increased serum aspirin-esterase activity in epileptics. Int J Clin Pharmacol Res 1989;9:309-311.
11. Luoma PV, Sotaniemi EA, Pelkonen RO, Myllylä VV: Plasma high-density lipoprotein cholesterol and hepatic cytochrome P450 concentrations in epileptics undergoing anticonvulsant treatment. Scan J Clin Lab Invest 1980;40:163-167.
12. Luoma PV, Sotaniemi EA, Pelkonen RO: Inverse relationship of serum LDL cholesterol and the LDL/HDL cholesterol ratio to liver microsomal enzyme induction in man. Res Commun Chem Pathol Pharmacol 1983;42:173-176.
13. Luoma PV, Sotaniemi EA, Arranto AJ: Serum LDL cholesterol, the LDL/HDL cholesterol ratio and liver microsomal enzyme induction evaluated by antipyrine kinetics. Scan J Clin Lab Invest 1983;43:671-675.
14. Luoma PV: Microsomal enzyme induction, lipoproteins and atherosclerosis. Pharmacol Toxicol 1988;62:243-249.
15. Sudhop T, Bauer J, Elger CE, Von Bergmann K: Increased high-density lipoprotein cholesterol in patients with epilepsy treated with carbamazepine: a gender-related study. Epilepsia 1999;40:480-484.
16. Eirís JM, Lojo S, Del Rio MC, Novo I, Bravo M, Pavón P, et al: Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology 1995;45:1155-1157.
17. Eirís J, Novo MI, Del Rio M, Meseguer P, Del Río MC, Castro-Gago M: The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic and phenobarbital therapy in children with epilepsy. Epilepsy Res 2000;41:1-7.
18. Isojärvi JIT, Pakarinen AJ, Myllylä VV: Serum lipid levels during carbamazepine medication: a prospective study. Arch Neurol 1993; 50:590-593.
19. Pita-Calandre E, Rodríguez-López CM, Cano MD, Peña-Bernal M: Lípidos, lipoproteínas y apoliproteí nas séricas en epilépticos adultos tratados con carbamazepina, ácido valproico o fenitoína. Rev Neurol 1998;27:785-789.
20. Brämswig S, Kersiek A, Sudhop T, Luers C, Von Bergmann K, Berthold HK: Carbamazepine increases atherogenic lipoproteins: mechanism of action in male adults. Am J Physiol Heart Circ Physiol 2002;282:H704-H716.
21. Tutor JC, Fernández-Vigo J, Paz JM, Villanueva MC, Cordido M: Actividad sérica de la β-glucuronidasa, gamma-glutamiltransferasa y colinesterasa en la diabetes mellitus y su relación con los niveles de lipoproteinas. Anal Clin 1990;15:39-46.
22. Abbott CA, Mackness MI, Kumar S, Olukoga AO, Gordon C, Arrol S, et al: Relationship between butyrylcholinesterase activity, hypertriglyceridemia and insulin sensitivity in diabetes mellitus. Clin Sci 1993;85:77-81.
23. Magarian EO, Dietz A: Correlation of cholinesterase with serum lipids and lipoproteins. J Clin Pharmacol 1987;27:819-820.
24. Lehtonen A, Marniemi J, Inberg M, Maatela J, Alanen E, Niittymäki K: Levels of serum lipids, apolipoproteins A-I and B and pseudocholinesterase activity and their discriminative values in patients with coronary by-pass operation. Atherosclerosis 1986;59:215-221.
25. Batt AM, Siest G, Magdalou J, Galteau MM: Enzyme induction by drugs and toxins. Clin Chim Acta 1992;209:109-121.
26. Richens A, Rowe DJF: Disturbance of calcium metabolism by anticonvulsant drugs. Br Med J 1970;4:73-76.
27. Rosalki SB: Plasma enzyme changes and their interpretation in patients receiving anticonvulsant and enzyme-inducing drugs, in: Richens A, Woodford FP (eds.), Anticonvulsant Drugs and Enzyme Induction. Amsterdam: Associated Scientific Publishers, 1976; 27-35.
28. den Blaauwen DH, Poppe WA, Tritschler W: Cholinesterase (EC 3.1.1.8) mit butyrilthiocholin-iodid als substrat: referenzwerte in abhägigkeit von alter, geslecht unter berüksichtigung hormonaler einflüsse und swangerschaft. J Clin Chem Clin Biochem 1983;21:381-386.
29. Fernández MP, Tutor JC, Paz JM: Determinación del ácido D-glucárico urinario por un procedimiento enzimático. Clin Chem Newsletter 1982;2:77-81.
30. Makki KA, Beetham R, Richens A: Overnight urine specimens for the determination of D-glucaric acid excretion in man. Br J Clin Pharmacol 1979;8:183-186.
31. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
32. Kutty KM, Jain R, Huang SN, Kean K: Serum pseudocholinesterase: high density lipoprotein cholesterol ratio as an index for cardiovascular disease. Clin Chim Acta 1981;115:55-61.
33. Jain R, Kutty KM, Huang SN, Kean K: Pseudocholinesterase/high-density lipoprotein cholesterol ratio in serum of normal persons and of hyperlipoproteinemics. Clin Chem 1983;29:1031-1033.
34. Wiltfang J, Schenk-Dapra B, Stiens G, Bleich S, Bandelow B, Müller P, Niedman PD, et al: Clozapine-associated elevation of plasma cholinesterase. Eur Arch Psychiatry Clin Neurosci 2001; 251:269-271.
35. Kragh-Hansen U, Chuang VTG, Otagiri M: Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol Pharm Bull 2002;25:695-704.
36. Chapuis N, Brühlmann C, Reist M, Carrupt PA, Mayer JM, Testa B: The esterase-like activity of serum albumin may be due to cholinesterase contamination. Pharm Res 2001;18:1435-1439.
37. Perucca E, Hedges A, Makki KA, Ruprah M, Wilson JF, Richens A: A comparative study of the relative enzyme inducing properties of auticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984; 18:401-410.
38. Hermida J, Fernández MP, Tutor JC: Relationship between changes in drug score, D-glucaric acid excretion and gamma-glutamyltransferase and beta-glucuronidase serum activities during anticonvulsant treatment. Clin Lab 2002;48:415-419.
39. Tutor-Crespo MJ, Hermida J, Tutor JC: Estudio de algunos marcadores bioquímicos indirectos en la evaluación de la inducción enzimática por fármacos antiepilépticos. Rev Neurol 2002;35:711-716.
40. Ratanasavanh D, Magdolou J, Antoine B, Galteau MM, Siest G: Gamma-glutamyltransferase activity of liver plasma membranes in phenobarbital-treated rabbits. Pharmacol Res Commun 1981;13:909-919.
41. Ratanasavanh D, Tazi A, Gaspart E, Jacquier A, Notter D, Galteau MM, et al: Hepatic gamma-glutamyltransferase release: effect of bile salts and membrane structure modifications, in: Siest G, Eusghen C (eds.), Gamma- Glutamyltransferases. Advances in Biochemical Pharmacology, 3rd series. Paris: Masson, 1982;92-103.
42. Jallon P, Picard F: Body weight gain and anticonvulsants: a comparative review. Drug Saf 2001;24:969-978.
43. Chu MI, Fontaine P, Kutty KM, Murphy D, Redheendran R: Cholinesterase in serum and low density lipoprotein of hyperlipemic patients. Clin Chim Acta 1978;85:55-59.
44. Kutty KM, Kean KT, Jain R, Huang S: Plasma pseudocholinesterase: a potential marker for early detection of obesity. Nutr Res 1983;3:211-216.
45. Demircioglu S, Soylu A, Dirik E: Carbamazepine and valproic acid: effects on the serum lipid and liver functions in children. Pediatr Neurol 2000;23:142-146.
46. Savolainen MJ, Arranto AJ, Hassinen IE, Luoma PV, Pelkonen PV, Sotaniemi EA: Relationship between lipid composition and drug metabolizing capacity of human liver. Eur J Clin Pharmacol 1985; 25:727-732.
47. Farombi EO, Akinloye O, Akinmoladun CO, Emerole GO: Hepatic drug metabolizing enzyme induction and serum triacylglycerol elevation in rats treated with chlordiazepoxide, griseofulvin, rifampicin and phenytoin. Clin Chim Acta 1999;289:1-10.
48. Whitfield JB, Zhu G, Nestler JE, Heath AC, Martin NG: Genetic covariation between serum γ-glutamyltransferase activity and cardiovascular risk factors. Clin Chem 2002;48:1426-1431.
49. Krijgsman B, Hamilton G, Mikhailidis DP: γ-glutamyltransferase and vascular disease. Clin Chem 2003;49:522-523.
50. Jokanovic M, Macsimovic M: Abnormal cholinesterase activity: understanding and interpretation. Eur J Clin Chem Clin Biochem 1997;35:11-16.